Earnings growth forecast for next year: Neurogene Corp (NGNE)
Neurogene Inc. develops unique gene therapy methods for rare brain pathologies, leveraging long-term patent protection. The expected change in net income confirms this trend, where the value of -2.90 corresponds to the current metric. Management is efficiently allocating resources to obtain clinical data, while the development strategy is based on academic alliances and independent research.
Neurogene - analytical breakdowns and key metrics (NGNE)
- share price and consensus valuation forecast:
- company stock exchange capitalization indicators:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Neurogene Inc.|NGNE - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Neurogene Therapeutics|NGNE - Company Total Debt Obligations|Debt to Book Capitalization Ratio Neurogene Therapeutics|NGNE - Company Long-Term Indebtedness|Company Short-Term Debts Neurogene|Quick Liquidity Indicator neurogene.com
- net income and valuation ratios data:
NGNE - Net Financial Result|Expected Profit Neurogene Inc.|NGNE - Price to Earnings Multiple|Forward P/E Multiple neurogene.com|NGNE - Price to Net Income Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neurogene Therapeutics|NGNE - Operating profit before amortization|Net earnings per share (EPS TTM) Neurogene|NGNE - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months neurogene.com|NGNE - Earnings per share growth this year|Earnings growth forecast for next year Neurogene Inc.
- issuer revenue and sales details:
Initial company analysis:NGNE, Neurogene
Asset managers require an objective assessment of an issuer's return potential to minimize the risk of overpayment. This indicator measures analysts' average expectations for net income changes, reflecting future business efficiency. By analyzing forward earnings per share (EPS) trends, an investor determines the company's overall growth trajectory. For Neurogene Inc. (NGNE), this forecast is critical, as successful patenting of gene therapy ensures a sharp transition from R&D expenditures to superprofits.
Competing companies
Net earnings per share growth forecast for next year Biogen|Expected earnings per share growth for next year neurocrine.com (NBIX)|Net earnings per share growth forecast for next year Regencell Bioscience Holdings Limited (RGC)|AXSM (Axsome Therapeutics Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year ACADIA Pharmaceuticals Inc. ACAD|Expected earnings per share trend next year XENE|Viking Therapeutics - Earnings growth forecast for next year|Expected earnings per share trend next year SUPN (supernus.com)|Catalyst Pharmaceuticals (CPRX) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Denali (DNLI)|Net earnings per share growth forecast for next year harmonybiosciences.com|BHVN (Biohaven Pharmaceutical) - Projected earnings per share increase next year|Net earnings per share growth forecast for next year amylyx.com (AMLX)|TRVI: Net earnings per share change forecast for next year|Net earnings per share growth forecast for next year Praxis Precision Medicines Inc PRAX|Consensus forecast of earnings per share growth for next year Anavex Life Sciences Corp. (AVXL)|CeriBell EEG - Earnings growth forecast for next year|Expected net earnings per share growth next year Prothena Corp|ALEC: Earnings growth forecast for next year|Projected earnings per share growth rate for next year ANNX|OMER (Omeros) - Earnings growth forecast for next year|Earnings growth forecast for next year AC Immune S.A.|Expected earnings per share growth for next year VYGR (Voyager Therapeutics, Inc.)|Projected earnings per share increase next year NMRA|Net earnings per share growth forecast for next year scilexholding.com SCLX|TVGN: Projected earnings per share growth rate for next year|alphacognition.com - Earnings growth forecast for next year|Cognition Therapeutics - Projected earnings per share increase next year|IKT: Earnings growth forecast for next year|Expected earnings per share growth for next year Cassava Sciences, Inc.|ASRT (assertiotx.com) - Earnings growth forecast for next year|Expected earnings per share growth for next year Coya Therapeutics (COYA)|Expected earnings per share growth for next year VTGN (Vistagen)|Consensus forecast of earnings per share growth for next year Ovid Therapeutics Inc|Earnings growth forecast for next year ABOS (Acumen Pharmaceuticals Inc.)|CRVO - Expected earnings per share growth for next year|Alterity Therapeutics Limited - Earnings growth forecast for next year|Expected net earnings per share growth next year Clene Inc|PEPG: Earnings growth forecast for next year|Expected earnings per share growth for next year jupiterneurosciences.com|RLMD (relmada.com) - Earnings growth forecast for next year|Earnings growth forecast for next year Annovis Bio Corporation|Earnings growth forecast for next year GRCE|AIFF: Net earnings per share change forecast for next year|Net earnings per share growth forecast for next year Klotho Neurosciences KLTO|NRSN: Projected earnings per share growth rate for next year|RVPH: Expected earnings per share growth for next year|Consensus forecast of earnings per share growth for next year MetaVia MTVA|neuraxis.com (NRXS) - Net earnings per share growth forecast for next year|Helius Medical Technologies Inc. - Expected earnings per share trend next year|PASG (Passage Bio, Inc.) - Earnings growth forecast for next year|bionomics.com.au - Net earnings per share change forecast for next year|Earnings growth forecast for next year NERV|ATHA (Athira) - Expected earnings per share trend next year|Addex Therapeutics - Expected earnings per share growth for next year|ALZN - Expected earnings per share growth for next year|Cyclerion Therapeutics, Inc. - Earnings growth forecast for next year|Expected earnings per share trend next year PTIX (Protagenic Therapeutics, Inc.)|KTTA (pasitheaclinics.com) - Expected earnings per share growth for next year|Projected earnings per share growth rate for next year CRGT|Expected earnings per share growth for next year ATXI|Expected earnings per share growth for next year Brainstorm Cell (BCLI)|Expected earnings per share growth for next year CARA (Cara Therapeutics, Inc.)|Expected earnings per share growth for next year Chromocell Therapeutics Corp CHRO|Earnings growth forecast for next year ELYM (Eliem Therapeutics, Inc.)|Earnings growth forecast for next year intracellulartherapies.com ITCI|Longboard Pharmaceuticals - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Marinus Pharmaceuticals, Inc. MRNS|NKGN: Earnings growth forecast for next year|NeuroBo Pharmaceuticals Inc - Expected earnings per share trend next year|SAGE (Sage Therapeutics Inc.) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year SNPX (Neurotrope)|Net earnings per share growth forecast for next year Trevena Inc. (TRVN)|VIGL - Expected net earnings per share growth next year|Anew Medical Inc. - Expected earnings per share growth for next year|CERE (Cerevel Therapeutics, Inc.) - Net earnings per share change forecast for next year
